Ivosidenib Shows Durable Disease Control in Advanced IDH1-Mutant Chondrosarcoma
Published: Friday, Apr 10, 2020
William D. Tap, MD
Ivosidenib (Tibsovo) showed minimal toxicity, substantial 2-hydroxyglutarate (2-HG) reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone, according to data from a phase I study.
... to read the full story